tiprankstipranks
Advertisement
Advertisement

GILD Stock Latest News

Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
RatingsGilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
5d ago
GILD
Gilead files automatic mixed securities shelf
PremiumThe Fly
Gilead files automatic mixed securities shelf
7d ago
GILD
Gilead price target lowered to $150 from $156 at Truist
PremiumThe Fly
Gilead price target lowered to $150 from $156 at Truist
8d ago
GILD
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
PremiumRatings
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
8d ago
GILD
Gilead price target raised to $123 from $120 at RBC Capital
PremiumThe Fly
Gilead price target raised to $123 from $120 at RBC Capital
8d ago
GILD
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
PremiumRatingsGilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
8d ago
GILD
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Premium
Ratings
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
8d ago
GILD
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
Premium
The Fly
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
9d ago
GILD
Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)
PremiumThe Fly
Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)
9d ago
GILD
Options Volatility and Implied Earnings Moves Today, August 04, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, August 04, 2026
9d ago
ET
AMD
Gilead update on California ruling removes an overhang, says UBS
PremiumThe Fly
Gilead update on California ruling removes an overhang, says UBS
10d ago
GILD
Gilead’s GS-2426 Phase 1 Trial Targets MTAP-Deleted Tumors: What Investors Should Know
PremiumCompany Announcements
Gilead’s GS-2426 Phase 1 Trial Targets MTAP-Deleted Tumors: What Investors Should Know
10d ago
GILD
Options Volatility and Implied Earnings Moves This Week, August 03 – August 06, 2026
PremiumMarket NewsOptions Volatility and Implied Earnings Moves This Week, August 03 – August 06, 2026
10d ago
O
ET
Is GILD a Buy, Before Earnings?
Premium
Pre-Earnings
Is GILD a Buy, Before Earnings?
11d ago
GILD
Gilead’s Twice-Yearly HIV Strategy: What the New Phase 3 Study Means for Investors
Premium
Company Announcements
Gilead’s Twice-Yearly HIV Strategy: What the New Phase 3 Study Means for Investors
14d ago
GILD
Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth
PremiumRatings
Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth
15d ago
GILD
Gilead price target lowered to $145 from $155 at Barclays
PremiumThe Fly
Gilead price target lowered to $145 from $155 at Barclays
15d ago
GILD
Gilead price target lowered to $165 from $166 at Morgan Stanley
PremiumThe Fly
Gilead price target lowered to $165 from $166 at Morgan Stanley
17d ago
GILD
Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer
PremiumThe Fly
Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer
20d ago
MRK
GILD
Gilead Advances Long-Acting HIV Regimen in New Phase 3 Head‑to‑Head Trial
PremiumCompany AnnouncementsGilead Advances Long-Acting HIV Regimen in New Phase 3 Head‑to‑Head Trial
22d ago
GILD
Gilead to present new HIV research at AIDS 2026
Premium
The Fly
Gilead to present new HIV research at AIDS 2026
23d ago
GILD
Gilead, Merck report ‘high’ rates of virologic suppression in ISLEND trials
Premium
The Fly
Gilead, Merck report ‘high’ rates of virologic suppression in ISLEND trials
23d ago
MRK
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >